- Home
- BGI vs INKT Comparison
BGI vs INKT Comparison
Compare BGI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- INKT
- Stock Information
- Founded
- BGI 1879
- INKT 2017
- Country
- BGI Canada
- INKT United States
- Employees
- BGI N/A
- INKT N/A
- Industry
- BGI
- INKT Medicinal Chemicals and Botanical Products
- Sector
- BGI
- INKT Health Care
- Exchange
- BGI Nasdaq
- INKT Nasdaq
- Market Cap
- BGI 31.1M
- INKT 34.9M
- IPO Year
- BGI 2005
- INKT 2021
- Fundamental
- Price
- BGI $1.46
- INKT $1.06
- Analyst Decision
- BGI
- INKT Strong Buy
- Analyst Count
- BGI 0
- INKT 2
- Target Price
- BGI N/A
- INKT $6.50
- AVG Volume (30 Days)
- BGI 6.0K
- INKT 216.6K
- Earning Date
- BGI 11-27-2024
- INKT 11-14-2024
- Dividend Yield
- BGI N/A
- INKT N/A
- EPS Growth
- BGI N/A
- INKT N/A
- EPS
- BGI N/A
- INKT N/A
- Revenue
- BGI $131,596,264.00
- INKT N/A
- Revenue This Year
- BGI N/A
- INKT N/A
- Revenue Next Year
- BGI N/A
- INKT N/A
- P/E Ratio
- BGI N/A
- INKT N/A
- Revenue Growth
- BGI 4.01
- INKT N/A
- 52 Week Low
- BGI $1.39
- INKT $0.46
- 52 Week High
- BGI $4.37
- INKT $1.90
- Technical
- Relative Strength Index (RSI)
- BGI 34.54
- INKT 60.31
- Support Level
- BGI $1.45
- INKT $0.82
- Resistance Level
- BGI $1.52
- INKT $0.98
- Average True Range (ATR)
- BGI 0.06
- INKT 0.13
- MACD
- BGI 0.00
- INKT 0.02
- Stochastic Oscillator
- BGI 26.61
- INKT 47.37
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.